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1. Introduction
Drug induced liver injury (DILI) is a primary safety 
concern during drug discovery and those drugs which 
are found to be associated with severe adverse drug 
reactions (ADRs) are mainly withdrawn from the market. 
There are few drugs which have been withdrawn due 
to its severe ADRs reported over the period of time in 
the post-marketing surveillance (PMS) [summarized in 
Table 1] and Ranitidine (RAN) is one of them and it 
is found to be associated with idiosyncratic hepatotoxic 
reactions (Teschke et al., 2018). RAN is widely used in 
the treatment of gastrointestinal diseases and is one of the 
most frequently prescribed drugs worldwide (Chalasani et 
al., 2010). An estimated 34.2 ± 10.7 cases of DILI per 1 
million people per year were reported in the Spanish DILI 
Registry. It has been observed that, amongst all the DILI 
cases about 53% had to be hospitalized, 2% undergone 
liver transplant, 10% and 5% had a chronic liver disease 
and acute liver disease respectively (Andrade et al., 
2005). DILI is a major reason behind the withdrawal 
of various pharmaceutical products. RAN induced liver 
injury may be an associated factor for its withdrawal from 
pharmaceutical market (Kaplowitz et al., 2005). Based on 
its clinical characteristics, RAN induced hepatotoxicity 
can be classified as cholestatic (mainly an increase in 
alkaline phosphatase, ALP), hepatocellular (primarily an 
increase in alanine aminotransferase, ALT) and mixed 
hepatotoxicity depending upon the type of observed liver 
injury.
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Background: Ranitidine (RAN) is one of the common drugs associated with idiosyncratic 
adverse drug reactions (IADRs) in humans. It was found to be associated with severe adverse drug 
reactions due to the presence of contaminants such as N-Nitrosodimethylamine (NDMA) which 
is claimed to be carcinogenic. As a consequence, on April 1, 2020, United States Food and Drug 
Administration (USFDA) had decided to call off all the RAN products from the market. The exact 
cause of RAN associated idiosyncratic hepatotoxicity is not clear yet.
Purpose: To summarize and analyze the reason behind the withdrawal of RAN products from the 
market and whether ranitidine will be available again in future or will FDA withdraw approvals 
of ranitidine National Drug Authority (NDA) and an abbreviated new drug application (ANDA)?
Methods: We performed a systematic PubMed/MEDLINE search of studies investigating the 
reason behind the withdrawal of RAN products and explored the possible mechanism associated 
with RAN induced hepatotoxicity.
Conclusion: RAN induced liver injury is difficult to diagnose and study because of its relative rarity 
and unpredictive occurrence. Recent studies suggest that most of the RAN associated idiosyncratic 
reactions may lead to hepatocyte damage, followed by a series of events, such as activation of 
specific T- and B-cells, release of proinflammatory mediators like TNFα, interleukins, various 
cytokines and chemokines. The exact cause of RAN associated idiosyncratic hepatotoxicity is not 
clear yet. More studies must be carried out on this to know about the exact reason behind RAN 
associated hepatotoxicity.
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Table 1: List of drugs called off due to hepatotoxicity worldwide.
S. No. Drug name Withdrawn Country Remarks Reference
1. Xenazoic acid 1965 France Hepatotoxicity Fung et al., 2001
2. Phenoxypropazine 1966 UK Hepatotoxicity, drug interaction Fung et al., 2001
3. Ibufenac 1968 UK Hepatotoxcity Fung et al., 2001
4. Fenclozic acid 1970 UK, US Hepatotoxicty Fung et al., 2001
5. Diacetoxydiphenolisatin 1971 Australia Hepatotoxicity Fung et al., 2001
6. Triacetyldiphenolisatin 1971 Australia Hepatotoxicity Fung et al., 2001
7. Nialamide 1974 UK, US Hepatotoxicity, drug interaction Fung et al., 2001
8. Mebanazine 1975 UK Hepatotoxicity, drug interaction Fung et al., 2001
9. Ticrynafen (Tienilic acid) 1980 Germany, UK, 
US, France
Liver toxicity and death. Fung et al., 2001
10. Benoxaprofen 1982 Germany, 
Spain, US, UK
Liver and kidney failure; 
gastrointestinal bleeding; ulcers.
Qureshi et al., 2011; Fung 
et al., 2001
11. Clomacron 1982 UK Hepatotoxicty Fung et al., 2001
12. Zimelidine 1983 Worldwide Hepatotoxicty Fung et al., 2001; Fagius 
et al., 1985
13. Isaxonine phosphate 1984 France Hepatotoxcity Fung et al., 2001
14. Clometacin 1987 France Hepatotoxicty Fung et al., 2001
15. Cyclofenil 1987 France Hepatotoxicity Fung et al., 2001
16. Exifone 1989 France Hepatotoxicty Fung et al., 2001
17. Pirprofen 1990 France, Spain, 
Germany
Liver toxicity Fung et al., 2001
18. Dilevalol 1990 UK Hepatotoxicty Fung et al., 2001
19. Fipexide 1991 France Hepatotoxicty Fung et al., 2001
20. Bendazac 1993 Spain Hepatotoxicity Fung et al., 2001
21. Alpidem (Ananxyl) 1995 Worldwide Not approved in US, withdrawan 
in France in 1994 and the rest of 
the market in 1995 because of 
rare but serious hepatotoxicity.








Hepatotoxicity & Steven-Johnson 
Syndrome
Fung et al., 2001
23. Tolrestat (Alredase) 1996 Argentina, 
Canada, Italy, 
others
Severe form of hepatotoxicity Fung et al., 2001
24. Pemoline (Cylert) 1997 Canada, UK Withdrawn from US in 2005. 
Hepatotoxicity
Drug Bank website
25. Ebrotidine 1998 Spain Hepatotoxicty Fung et al., 2001




Hepatotoxicty Fung et al., 2001
27. Troglitazone (Rezulin) 2000 Germany, US Hepatotoxicity Qureshi et al., 2011
28. Kava Kava 2002 Germany Hepatotoxicity Schubert-Zsilavecz, 2011
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29. Alatrofloxacin 2006 Worldwide Serious liver injury leading to liver 
transplant or death.
Qureshi et al., 2011
30. Ximelagatran (Exanta) 2006 Germany Hepatotoxicity Schubert-Zsilavecz, 2011
31. Lumiracoxib (Prexige) 2007-2008 Worldwide Liver damage Qureshi et al., 2011
32. Sitaxentan 2010 Germany Hepatotoxicity Schubert-Zsilavecz, 2011
33. Flupirtine 2018 European 
Union
Liver toxicity European Medicines 
Agency, 2018
34. Ranitidine 2020 US Hepatotoxicity, idiosyncratic 
hepatotoxic reactions







Hepatotoxicity Fung et al., 2001
Scientific data showed that there are numerous drugs, 
such as Ranitidine, Cimetidine and Famotidine, which 
are responsible for induction of hepatotoxicity. Hepatic 
cellular dysfunction initiates various immunological 
reactions such as innate and adaptive immune responses. 
Stress and/or damage to the hepatocytes may trigger the 
activation of Kupffer cells (KC), natural killer cells (NK) 
and natural killer T (NKT) cells which enhance the release 
of various pro-inflammatory mediators and chemokines 
in the liver (Blazka et al., 1995; Blazka et al., 1996; Ishida 
et al., 2002). Although, RAN induced liver injury subsides 
after the termination of drug treatment, still it is a major 
diagnostic and therapeutic concern for doctors. Majority of 
RAN associated liver injury cases are not recognized during 
clinical trials, later on they are reported in post marketing 
surveillance. There is a lack of preclinical and clinical studies 
on ranitidine, but there are some case studies [summarized 
in Table 2] which evidenced that ranitidine therapy raises 
the risk of liver disorders (Alfirevic et al., 2012). The present 
review focuses on the possible mechanism behind the 
etiology of RAN induced liver toxicity and reason behind 
the withdrawal of RAN from the market.
Table 2: Case study reports on ranitidine therapy.
S. 
No.













2 weeks 10 days (Barr et al., 
1981)
2. 66 year old 150 mg 
daily
mild focal necrosis, with moderate portal 




4 week 1 week (Offit et 
al.,1984)









3 days 2weeks (Souza et al., 
1984)




mild elevations in serum alanine 





2 weeks 4 weeks (Devuyst et al., 
1993)
5. 29 year old man 





marked elevations in serum bilirubin, mild 




2 weeks 2-3 month (Ramrakhiani 
et al., 1998)
6. 73 year old 150 mg 
twice daily
hyperbilirubinemia (15.6 mg/dL) with 
conjugated bilirubin, a 2.5-fold elevation 
of alkaline phosphatase and moderate 





3 weeks 50 days (Liberopoulos 
et al., 2002)
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2. History of Ranitidine Associated Toxicity
Ranitidine was first introduced by john Bradshaw in the UK 
as AH19065 in 1977 at the Ware research laboratories of 
Allen and Hanburys, division of a larger Glaxo organization 
(Lednicer, 1993). Further it was developed by Sir James 
Black at Smith, Kline and French in response to the first 
H2-receptor, antagonist, launched as Tagamet on November 
1976 in United Kingdom. Furthermore, Glaxo developed 
the model with modification to the structure to nitrogen 
containing substituent, i.e. substituting the cimetidine 
imidazole ring with a furan ring and creating ranitidine. 
The tolerance level of RAN (i.e. fewer adverse reactions) was 
said to be much better and more powerful than cimetidine. 
RAN has about 10% interaction with cytochrome P 450 
which indicates fewer side effects, but there are no major 
interactions with cytochrome P450 and other H2 blockers, 
such as nizatidine and famotidine (Newhouse, 1986). 
Ranitidine was the newly introduced and a United States 
Food and Drug Administration (US-FDA) approved H2 
receptor antagonist for short-term oral use in duodenal 
ulcer therapy and in the Zollinger-Ellison syndrome in 
hypersecretory states (Med Lett, 1982). Few reports of 
clinical hepatotoxicity have been reported in Europe, 
Australia and Canada while undergoing oral preparation 
therapy and symptomatic liver disease have occurred in the 
United States during treatment with oral ranitidine (Barr, 
1981; Cleator, 1983). A study showed that patients had 
symptomatic liver disease between 3 and 5 weeks after the 
ranitidine treatment, concerned symptoms like headache, 
“flu-like symptoms” (shaking chills and fever) and dark 
urine had also been observed for one day (Black et al., 1984). 
Recently, on April 1, 2020, the presence of 
contaminants was recognized as N-Nitrosodimethylamine 
(NDMA), the US-FDA immediately demanded the 
manufacturers for withdrawal of all the over-the-counter 
(OTC) and prescription RAN products. However in some 
of the samples, the US-FDA failed to detect inappropriate 
NDMA levels, they found that the contamination of some 
ranitidine products increased over the course of the time, 
when stored at higher room temperatures. As a consequence, 
ranitidine products are banned for use in the US (Lim et 
al., 2020). NDMA (a cancer causative agent) is a possible 
human carcinogen, and low NDMA levels are normally 
consumed in diets. These levels, do not contribute to rise 
in cancer risk. The US-FDA conducted comprehensive 
testing on ranitidine and found a very low level of NDMA 
and suggested to avoid the use of Ranitidine products. In 
September 2019, the US-FDA concluded its analysis and 
informed the people about possible hazards and proposed 
alternative OTC and prescription therapies (Francis et al., 
2005).
3. Molecular Mechanism Involved in 
Ranitidine Associated Hepatotoxicity 
It is believed that RAN induced hepatotoxicity involves 
two pathways i.e. Immune mediated (Immunoallergic 
reactions) and direct cellular dysfunction. Though, the exact 
mechanism behind ranitidine induced hepatotoxicity still 
remains unclear (Bleibel et al., 2007), a schematic diagram 
concerned with the possible mechanism of RAN induced 
hepatotoxicty has been hypothesized in Figure 1.
Figure 1: Illustration of pathways involved in ranitidine induced liver injury/ hepatotoxicity.
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3.1. Immune-Mediated Liver Injury (Immunoallergic 
reactions)
The liver contains abundant sinusoidal macrophages i.e. 
Kupffer cells, which are responsible for the removal of 
foreign antigens, cellular debris and waste via hepatic portal 
system. It promotes the activation of cytotoxic T cells and 
induces apoptotic death of activated T cells and suppresses 
the immune response against these foreign antigens thereby 
increase immune tolerance (Maddrey et al., 2005). In case of 
ranitidine associated liver injury this process gets disrupted 
and results in impaired immune tolerance and generate altered 
autoantigens (Bleibel et al., 2007). These autoantigens binds to 
the surface of B-cells and forms MHC type I with hepatocytes 
via antigen-antibody reaction which subsequently causes 
induction of autoimmune reactions or antibody dependent 
immune response or B-cell mediated humoral response 
which is responsible for cellular destruction of hepatocytes via 
phagocytosis (Bleibel et al., 2007). In addition, these cellular 
immune responses triggers the release of pro-inflammatory 
mediators and various cytokines such as Tumour Necrosis 
Factor α (TNFα), nitrogen oxide (NO), FasL, and various 
interferons particularly IFN-γ (Kaplowitz et al., 2004).
3.2. Direct Cellular Damage
In majority of cases, RAN induced liver injury is triggered 
by chemically active toxic metabolite of drug which binds to 
cellular components such as lipids, proteins, nucleic acids and 
other cellular organelles leading to direct cellular dysfunction 
such as altered protein synthesis, nuclear damage and lipid 
peroxidation, which subsequently increases mitochondrial 
oxidative stress and promotes hepatocellular damage (Holt 
et al., 2006). Additionally, this direct cellular damage 
also increases the sensitivity of cells to the TNF receptor 
(Particularly TNFα) which triggers apoptotic cascade 
activation and induces apoptosis and promotes phagocytosis 
by the activation of cytotoxic T-cells (CD8) and leads to 
necrotic or apoptotic damage of hepatocytes. There is lot of 
phenotypic genetic variation amongst people; some people are 
vulnerable to RAN associated idiosyncratic reactions, whereas 
some are resistant. The microsomal P450 is responsible for 
the metabolism of RAN. Patients who lack cytochrome P450 
enzyme  are more prone to idiosyncratic reactions, because in 
the absence of cytochrome P450, metabolism of ranitidine is 
affected which leads to formation of its toxic metabolites and 
various intermediates which are responsible for hepatocellular 
damage (Kaplowitz et al., 2004). 
4. Case Study Reports on Ranitidine Therapy
Ranitidine has been used for years in the treatment of 
gastrointestinal diseases and considered as the most 
prescribed drugs in the world. As DILIs are generally 
idiosyncratic, infrequent and unpredictable therefore 
difficult to induce in animal models therefore, either no 
or very fewer preclinical models have been developed for 
idiosyncratic DILI which makes it difficult to understand 
its exact pathogenesis (Chalasani et al., 2010). A few case 
studies have been tabulated in Table 2.
5. Steps Taken by Government and Any 
Regulations
US-FDA, European Medicines Agency (EMA), and 
Central Drugs Standard Control Organisation (CDSCO) 
have spotted the stringent content of nitrosamine in 
various products of RAN (Shaik et al., 2020). India’s drug 
regulatory authority has ordered to withdraw samples of 
RAN, after the US regulator declared the presence of a 
cancer-causing impurity in some products (Woodcock, 
2019). The Drug Controller General of India (DCGI) has 
asked the state drug regulators to withdraw all the samples 
of RAN from the major manufacturers and send those to 
Central Drug Laboratory (CDL) in Kolkata in order to 
test the impurity i.e. N-Nitrosodimethylamine (NDMA). 
Meanwhile, the appellate laboratory in Kolkata may not 
have the equipment to conduct the Liquid Chromatography-
High Resolution Mass Spectrometry (LC-HRMS) test which 
has been recommended by the US-FDA for testing NDMA 
in ranitidine products. Venues have now been explored to 
get these tests done by private analytical laboratories. The 
US-FDA has released an update on NDMA testing for 
ranitidine, which warns manufacturers that they should 
not perform the aforementioned test in high-temperature 
because they produce high impurities for the presence of 
NDMA (Teena Thacker, 2019). In India, GSK agreed to 
withdraw all dosage forms of ranitidine hydrochloride from 
the market due to the pending outcome of ongoing tests and 
investigations as a precautionary action in correspondence 
with regulatory authorities (The Hindu, 2019).
Conclusion
RAN induced liver injury is difficult to diagnose and study 
because of its relative rarity and unpredictive occurrence 
(Watkins et al., 2005). Recent studies suggest that most 
of the RAN associated idiosyncratic reactions may lead to 
hepatocyte damage, followed by a series of events, such as 
activation of specific T- and B-cells, release of proinflammatory 
mediators like TNFα, interleukins, various cytokines and 
chemokines. However RAN induced hepatotoxicity is self-
limiting in majority of cases, if early diagnosis is not made, 
then it may develop into severe hepatic failure (Rashid et al., 
2004). In a preclinical study, it was observed that ranitidine 
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(30 mg/kg) did not produce liver injury in healthy animals; 
it was hepatotoxic in only those rats which are having mild 
inflammatory response induced by LPS (Luyendyk et al., 
2003). The liver injury caused by RAN is usually rapidly 
reversible with cessation of the treatment. Gastroenterologists 
must be aware of the consequences before prescribing RAN 
to the patients who are already suffering from any liver 
diseases. The exact cause of RAN associated idiosyncratic 
hepatotoxicity is not clear yet. However, some studies suggest 
that the H2 receptor antagonists may be a potential cause 
for idiosyncratic hepatotoxic reactions; therefore it is not 
prescribed now-a-days. Due to the lack of preclinical and 
clinical studies on RAN associated liver injury, it is difficult 
to conclude the exact pathogenesis and the possible ADRs. 
However, Nitrosamines are genotoxic impurities, and due 
to their carcinogenicity, they pose an alarming threat to all 
creatures of earth. To alleviate this global issue, regulatory 
agencies such as CDSCO, US-FDA, and EMA have given 
their continuous effort for quantitative determination of 
amine impurities present in food stuffs, and in various 
intermediates in organic synthesis (Shaik et al., 2020). More 
studies must be carried out on this to know about the reason 
behind its hepatotoxicity.
Future Prospective
It is a topic of debate among various academicians and 
scientists “whether ranitidine will be available again in future 
or will FDA withdraw approvals of ranitidine (NDA) and 
An abbreviated new drug application (ANDA)?” However 
USFDA detected NDMA as a carcinogenic impurity still 
they failed to detect the optimum level or concentration at 
which it may harm the liver and other vital organs. There 
can be a possibility that RAN will come again in the market 
if the level of NDMA is found negligible or harmless 
concerned regarding patients health. There is a need to 
carry out more experimental studies in order to detect the 
optimum level of NDMA which is ultimately causing RAN 
associated hepatotoxicity.
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